D. Inwards

Sonali M. Smith, M. Norkin, D. Maloney, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma

J. Cerhan, T. Habermann, S. Slager, 2017, Blood Cancer Journal.

The effect of absolute lymphocyte count recovery kinetics on survival after autologous stem cell transplantation for non-Hodgkin's lymphoma

S. Ansell, A. Dispenzieri, A. Tefferi, 2005, Leukemia & lymphoma.

PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts

Jason R. Young, J. Cerhan, A. Feldman, 2021, Blood Cancer Journal.

Lower GVHD and relapse risk in PTCy-based Haploidentical vs Matched Sibling Donor RIC Transplant for Hodgkin Lymphoma

M. Aljurf, J. Bolaños-Meade, Y. Nieto, 2019 .

Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure

J. Vose, Sonali M. Smith, R. Vij, 2018, Cancer.

A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma

T. Habermann, P. L. Bergsagel, A. Dueck, 2018, Leukemia & lymphoma.

A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR‐CD) for untreated low‐grade non‐Hodgkin lymphoma requiring therapy

T. Habermann, R. Fonseca, D. Dingli, 2017, American journal of hematology.

The mTORC1 Inhibitor Everolimus Combined with R-CHOP-21 for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Safety and Efficacy Results of a Phase I and Feasibility Trial NCCTG 1085 (Alliance)

T. Habermann, S. Ansell, T. Witzig, 2016 .

A Phase 2 Study of Lenalidomide, Rituximab, Cyclophosphamide and Dexamethasone (LR-CD) for Untreated Low Grade Non-Hodgkin Lymphoma Requiring Therapy

T. Habermann, R. Fonseca, D. Dingli, 2015 .

Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma.

S. Montoto, P. Hari, D. Maloney, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

lymphoma: myeloablative or reduced intensity? Conditioning regimens for allotransplants for diffuse large B-cell

Sonali M. Smith, P. Hari, P. Armand, 2012 .

Day 15 peripheral blood lymphocyte/monocyte ratio post-autologous peripheral hematopoietic stem cell transplantation and survival in diffuse large B-cell lymphoma.

S. Ansell, S. Markovic, W. Hogan, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study

T. Habermann, S. Ansell, C. Reeder, 2011, Leukemia.

Outcomes of Autologous Stem Cell Transplant Consolidation in Primary CNS Lymphoma: A Mayo Clinic Experience.

T. Habermann, S. Ansell, B. Laplant, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Detection of t(2;5) in anaplastic large cell lymphoma: comparison of immunohistochemical studies, FISH, and RT-PCR in paraffin-embedded tissue.

S. Ansell, K. Pulford, D. Arber, 1999, The American journal of surgical pathology.

A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B‐cell non‐Hodgkin lymphoma

Brian J. Smith, Y. Asmann, T. Habermann, 2013, American journal of hematology.

Testicular lymphoma is associated with a high incidence of extranodal recurrence

B. O'neill, T. Habermann, L. Burgart, 2000, Cancer.

Prophylaxis of graft-versus-host disease with cyclosporine–prednisone is associated with increased risk of chronic graft-versus-host disease

W. Harmsen, A. Tefferi, M. Litzow, 2001, Bone Marrow Transplantation.

Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research.

S. Montoto, P. Hari, D. Maloney, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR.

J. Vose, J. Winter, P. Hari, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Malignant lymphoma of the bladder: evidence from 36 cases that low-grade lymphoma of the MALT-type is the most common primary bladder lymphoma.

D. Bostwick, P. Wollan, D. Inwards, 1997, The American journal of surgical pathology.

Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma

J. Cerhan, T. Habermann, K. Yost, 2018, Hematological oncology.

A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B‐cell lymphoma

T. Habermann, S. Ansell, S. Ansell, 2006, Cancer.

Single‐agent cladribine as an effective front‐line therapy for adults with Langerhans cell histiocytosis

Jason R. Young, J. Ryu, A. Pardanani, 2021, American journal of hematology.

Patients with celiac disease and B-cell lymphoma have a better prognosis than those with T-cell lymphoma.

T. Habermann, A. Rubio‐Tapia, J. Murray, 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Autologous haematopoietic cell transplantation for non‐Hodgkin lymphoma with secondary CNS involvement

J. Vose, S. Montoto, P. Hari, 2013, British journal of haematology.

Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center.

D. Dingli, S. Ansell, A. Dispenzieri, 2013, Bone Marrow Transplantation.

Immune reconstitution after autologous hematopoietic transplantation with Lin-, CD34+, Thy-1lo selected or intact stem cell products.

P. Bierman, J. Vose, J. Talmadge, 2007, International immunopharmacology.

Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis.

A. Dispenzieri, A. Tefferi, S. Ansell, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma

S. Ansell, S. Markovic, D. Gastineau, 2004, Bone Marrow Transplantation.

Superior Survival in Primary Systemic Amyloidosis Patients Undergoing Peripheral Blood Stem Cell Transplant : A Case Control Study Running Head: Survival in AL, Case Control Study

R. Fonseca, S. Ansell, A. Dispenzieri, 2004 .

Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate

S. Ansell, A. Dispenzieri, A. Tefferi, 2004, Bone Marrow Transplantation.

A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma

R. Fonseca, J. Sloan, P. Anderson, 2005, Leukemia.

Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study.

S. Ansell, S. Markovic, D. Gastineau, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-α in autologous stem cell transplantation

M. Lacy, D. Inwards, L. Porrata, 2001, Bone Marrow Transplantation.

Phase II trial of the oral mTOR inhibitor everolimus (RAD001) for patients with relapsed or refractory lymphoma

T. Habermann, S. Ansell, S. Markovic, 2007 .

Anti-tumor activity of mTOR inhibitor temsirolimus for relapsed mantle cell lymphoma: A phase II trial in the North Central Cancer Treatment Group.

S. Ansell, S. Dakhil, S. Kaufmann, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas.

T. Habermann, S. Ansell, Hui Tang, 2011, Blood.

Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis.

Sonali M. Smith, A. Zelenetz, J. Friedberg, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma.

S. Montoto, Sonali M. Smith, P. Hari, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes in primary cutaneous diffuse large B‐cell lymphoma, leg type

T. Habermann, S. Ansell, T. Witzig, 2021, Hematological Oncology.

Absolute Lymphocyte Count Recovery Predicts Superior Survival and Is Independent of the International Prognostic Index in Patients Treated with CHOP or R-CHOP Chemotherapy for Diffuse Large B Cell Lymphoma.

T. Habermann, S. Ansell, S. Markovic, 2005 .

Peri-engraftment respiratory distress syndrome during autologous hematopoietic stem cell transplantation

A. Tefferi, M. Lacy, U. Prakash, 2001, Bone Marrow Transplantation.

Mucosal CD30-positive T-cell lymphoproliferations of the head and neck show a clinicopathologic spectrum similar to cutaneous CD30-positive T-cell lymphoproliferative disorders

A. Feldman, A. Dogan, R. McClure, 2012, Modern Pathology.

Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study.

J. Cerhan, A. Feldman, T. Habermann, 2017, International journal of epidemiology.

A Phase II study of 153Sm‐EDTMP and high‐dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma

D. Dingli, S. Ansell, A. Dispenzieri, 2010, American journal of hematology.

Multiple myeloma associated with diffuse osteosclerotic bone lesions: A clinical entity distinct from osteosclerotic myeloma (POEMS syndrome)

R. Kyle, M. Gertz, M. Lacy, 1997, American journal of hematology.

Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma.

J. Vose, M. Aljurf, R. Gale, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Cancer Therapy : Clinical Phase I Study of Ipilimumab , an Anti – CTLA-4 Monoclonal Antibody , in Patients with Relapsed and Refractory B-Cell Non – Hodgkin Lymphoma

T. Habermann, S. Ansell, I. Lowy, 2009 .

Long‐term results of the treatment of patients with mantle cell lymphoma with cladribine (2‐CDA) alone (95‐80‐53) or 2‐CDA and rituximab (N0189) in the North Central Cancer Treatment Group

R. Fonseca, S. Ansell, T. Witzig, 2008, Cancer.

Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasone

T. Habermann, S. Ansell, S. Markovic, 2007, Leukemia & lymphoma.

Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease.

W. Chan, D. Weisenburger, J. Armitage, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fatal Disseminated Aspergillosis following Sequential Heart and Stem Cell Transplantation for Systemic Amyloidosis

M. Gertz, J. Dearani, R. Razonable, 2001, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Long-Term Health-Related Quality of Life of Autologous Hematopoietic Cell Transplantation Patients and Nontransplant Patients With Aggressive Lymphoma: A Prospective Cohort Analysis

J. Cerhan, S. Ansell, S. Ehlers, 2022, JCO oncology practice.

Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience.

D. Dingli, A. Dispenzieri, R. Kyle, 2012, Blood.

Factors influencing platelet recovery after blood cell transplantation in multiple myeloma

R. Kyle, A. Tefferi, M. Gertz, 1997, Bone Marrow Transplantation.

Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximab.

T. Habermann, J. Gross, T. Witzig, 2007, Mayo Clinic proceedings.

Risk of histological transformation and therapy‐related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma

T. Habermann, S. Ansell, S. Markovic, 2017, British journal of haematology.

Event-Free Survival at 12 Months (EFS12) from Diagnosis Is a Robust Endpoint for Disease-Related Survival in Patients with Follicular Lymphoma in the Immunochemotherapy Era

J. Cerhan, A. Feldman, T. Habermann, 2014 .

PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts

Jason R. Young, J. Cerhan, A. Feldman, 2021, Blood Cancer Journal.

Spontaneous Complete Remission of Angioimmunoblastic T-Cell Lymphoma

D. Inwards, J. Liang, M. Howard, 2014, Proceedings.

The International Prognostic Index predicts outcome after histological transformation of low-grade non-Hodgkin lymphoma

T. Habermann, S. Ansell, S. Markovic, 2006, Leukemia & lymphoma.

Acalabrutinib for mantle cell lymphoma.

T. Witzig, D. Inwards, 2019, Blood.

Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes

J. Cerhan, A. Feldman, T. Habermann, 2021, Blood advances.

Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality.

S. Montoto, Sonali M. Smith, P. Hari, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of lymphoma survivorship clinic visit on patient-centered outcomes.

T. Habermann, S. Ansell, S. Markovic, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma.

T. Witzig, B. Laplant, D. Wender, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma.

T. Witzig, B. Laplant, D. Wender, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Initial therapy of mantle cell lymphoma

T. Witzig, D. Inwards, 2011, Therapeutic advances in hematology.

Refractory and relapsing multiple myeloma treated by blood stem cell transplantation.

M. Gertz, P. Greipp, T. Witzig, 1995, The American journal of the medical sciences.

Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia

S. Ansell, A. Dispenzieri, A. Tefferi, 2006, Bone Marrow Transplantation.

Lymphocyte recovery after allogeneic bone marrow transplantation predicts risk of relapse in acute lymphoblastic leukemia

Santhosh K. P. Kumar, A. Tefferi, M. Lacy, 2003, Leukemia.

Interleukin-15 Affects Patient Survival through Natural Killer Cell Recovery after Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphomas

S. Ansell, S. Markovic, W. Hogan, 2010, Clinical and Developmental Immunology.

Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation

S. Ansell, S. Markovic, D. Inwards, 2022, Leukemia & lymphoma.

Therapeutic options in patients with lymphoma and severe liver dysfunction.

T. Habermann, R. Fonseca, S. Ansell, 2004, Mayo Clinic proceedings.

Veno-occlusive Disease of the Liver after Blood and Marrow Transplantation: Analysis of Pre- and Post-transplant Risk Factors Associated with Severity and Results of Therapy with Tissue Plasminogen Activator

K. Batts, P. Anderson, A. Tefferi, 2002, Leukemia & lymphoma.

Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma.

J. Cerhan, T. Habermann, S. Slager, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bowel perforation in intestinal lymphoma: incidence and clinical features.

T. Habermann, J. Donohue, S. Ansell, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Granulomatous angiitis of the spinal cord associated with Hodgkin's disease

B. Scheithauer, B. O'neill, T. Habermann, 1991, Cancer.

Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia

Shaji K. Kumar, A. Tefferi, M. Gertz, 2001, Bone Marrow Transplantation.

Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation

Sonali M. Smith, M. Perales, Q. Bashir, 2016, British journal of haematology.

Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma

R. Kyle, A. Tefferi, M. Gertz, 1999, Bone Marrow Transplantation.

Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research.

P. Hari, R. Gale, M. Cairo, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Rituximab Toxicity in Patients with Peripheral Blood Malignant B-cell Lymphocytosis

T. Habermann, S. Ansell, T. Witzig, 2001, Leukemia & lymphoma.

High-Dose Methotrexate in Patients With Lymphoma: Predictors of a Complicated Course

T. Habermann, S. Ansell, T. Witzig, 2022, JCO oncology practice.

Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma

A. Dispenzieri, A. Tefferi, S. Ansell, 2003, Bone Marrow Transplantation.

Cytogenetic findings in 21 cases of peripheral T‐Cell lymphoma

T. Habermann, P. Banks, G. Dewald, 1990, American journal of hematology.

Absolute lymphocyte count predicts therapeutic efficacy and survival at the time of radioimmunotherapy in patients with relapsed follicular lymphomas

T. Habermann, S. Ansell, S. Markovic, 2007, Leukemia.

Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report

D. Dingli, A. Dispenzieri, Shaji K. Kumar, 2010, Leukemia & lymphoma.

Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes

T. Habermann, A. Dispenzieri, R. Kyle, 2020, British journal of haematology.

Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilization

D. Dingli, S. Ansell, A. Dispenzieri, 2011, Bone Marrow Transplantation.

Pathologic and Clinical Features of Primary Pulmonary Extranodal Marginal Zone B-Cell Lymphoma of MALT Type

V. Pankratz, C. Lohse, J. Myers, 2001, The American journal of surgical pathology.

Host genetic variation in tumor necrosis factor and nuclear factor‐κB pathways and overall survival in mantle cell lymphoma: A discovery and replication study

J. Cerhan, Y. Asmann, N. Rothman, 2019, American journal of hematology.

Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative.

D. Dingli, A. Dispenzieri, Shaji K. Kumar, 2008, Mayo Clinic proceedings.

Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma.

T. Habermann, S. Ansell, T. Witzig, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: analysis after a minimum follow-up of 5 years

A. Dispenzieri, A. Tefferi, S. Ansell, 2008, Leukemia & lymphoma.

Central nervous system involvement by mantle cell lymphoma

T. Habermann, S. Ansell, T. Witzig, 2021, Leukemia & lymphoma.

Stem cell transplantation for the management of primary systemic amyloidosis.

A. Dispenzieri, A. Tefferi, S. Ansell, 2002, The American journal of medicine.

Successful treatment of simultaneous pulmonary Pseudallescheria boydii and Aspergillus terreus infection with oral itraconazole.

S. Goldberg, H. Hoagland, D. Inwards, 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

How to Interpret and Pursue an Abnormal Complete Blood Cell Count in Adults

Ayalew Tefferi, A. Tefferi, D. Inwards, 2005, Mayo Clinic Proceedings.

Role of systemic high‐dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990‐2018

T. Habermann, J. Pulido, T. Witzig, 2018, American journal of hematology.

Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome

D. Dingli, A. Bryce, A. Dispenzieri, 2008, European journal of haematology.

PAX5-positive T-cell Anaplastic Large Cell Lymphomas Associated with Extra Copies of the PAX5 Gene Locus

A. Feldman, A. Dogan, D. Inwards, 2010, Modern Pathology.

Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis

L. Lekakis, N. Ghosh, H. Lazarus, 2019, Journal of Hematology & Oncology.

Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning.

J. Vose, P. Hari, R. Gale, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance)

T. Habermann, S. Ansell, B. Laplant, 2017, Blood Cancer Journal.

Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.

T. Habermann, S. Ansell, T. Witzig, 2016, The Lancet. Haematology.

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.

R. Fonseca, S. Dakhil, S. Kaufmann, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma

T. Habermann, S. Ansell, D. Northfelt, 2017, American journal of hematology.

Composite hodgkin and non-hodgkin lymphoma of the mitral and aortic valves.

A. Feldman, H. Burkhart, D. Inwards, 2010, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma

A. Tefferi, M. Gertz, P. Greipp, 2000, Bone Marrow Transplantation.

Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource.

J. Cerhan, T. Habermann, S. Slager, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.

Ash A. Alizadeh, R. Tibshirani, J. Vose, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes in primary cutaneous diffuse large B‐cell lymphoma, leg type

T. Habermann, S. Ansell, T. Witzig, 2021, Hematological oncology.

A Prognostic Model Predicting Autologous Transplantation Outcomes in Children, Adolescents and Young Adults with Hodgkin Lymphoma

J. Vose, Sonali M. Smith, W. Wood, 2015, Bone Marrow Transplantation.

Lymphoid reconstitution Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia

A. Tefferi, D. Inwards, S. Kumar, 2001 .

Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant.

P. Riedell, F. Awan, M. Krem, 2021, JAMA oncology.

Outcomes of older adults with non-Hodgkin lymphoma undergoing autologous stem cell transplantation: a Mayo Clinic Cohort Analysis.

S. Ansell, W. Hogan, D. Inwards, 2022, Transplantation and cellular therapy.

Brexucabtagene autoleucel therapy induces complete remission in a primary refractory blastoid mantle cell lymphoma with neurolymphomatosis

Jason R. Young, D. Inwards, A. Khurana, 2021, American journal of hematology.

The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma

T. Habermann, S. Ansell, S. Markovic, 2011, Leukemia.

Acquired C1 Esterase Inhibitor Deficiency

S. Markovic, D. Inwards, E. Frigas, 2000, Annals of Internal Medicine.

Acquired C1 esterase inhibitor deficiency.

S. Markovic, D. Inwards, E. Frigas, 2000, Annals of internal medicine.

Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas

T. Habermann, S. Ansell, S. Markovic, 2007, British journal of haematology.

Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma.

S. Ansell, A. Dispenzieri, A. Tefferi, 2001, Blood.

Clinicopathologic and Genetic Characterization of Follicular Lymphomas Presenting in the Ovary Reveals 2 Distinct Subgroups

A. Feldman, G. Keeney, A. Dogan, 2011, The American journal of surgical pathology.

A randomized, placebo-controlled study of outpatient premedication for bone marrow biopsy in adults with lymphoma.

T. Habermann, T. Witzig, P. Wilson, 2000, Clinical lymphoma.

Predicting survival for diffuse large B‐cell lymphoma patients using baseline neutrophil/lymphocyte ratio

T. Habermann, S. Markovic, K. Ristow, 2010, American journal of hematology.

Alternate donor hematopoietic cell transplantation (HCT) in non-Hodgkin lymphoma using lower intensity conditioning: a report from the CIBMTR.

S. Montoto, P. Hari, R. Gale, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies

S. Ansell, M. Lacy, W. Hogan, 2010, Bone Marrow Transplantation.

A Risk Adapted Approach Utilizing Plerixafor in Autologous Peripheral Blood Stem Cell Mobilization.

D. Dingli, A. Dispenzieri, Shaji K. Kumar, 2009 .

Characteristics of late transplant‐associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation

D. Dingli, A. Dispenzieri, Shaji K. Kumar, 2020, American journal of hematology.

Autograft immune content and survival in non-Hodgkin's lymphoma: A post hoc analysis.

S. Ansell, S. Markovic, D. Inwards, 2019, Leukemia research.

Immunologic Autograft Engineering and Survival in Non-Hodgkin Lymphoma.

S. Ansell, V. Suman, S. Markovic, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Predicting Peripheral Blood Stem Cell Harvest Failure Using Circulating CD34 Levels: Developing Target-Based Cut-Points for Early Intervention

D. Dingli, A. Dispenzieri, S Kumar, 2010, Bone Marrow Transplantation.

Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization.

D. Dingli, A. Dispenzieri, Shaji K. Kumar, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Clinical Study Day 100 Peripheral Blood Absolute Lymphocyte / Monocyte Ratio and Survival in Classical Hodgkin ’ s Lymphoma Postautologous Peripheral Blood Hematopoietic Stem Cell Transplantation

S. Ansell, S. Markovic, W. Hogan, 2015 .

Day 100 Peripheral Blood Absolute Lymphocyte/Monocyte Ratio and Survival in Classical Hodgkin's Lymphoma Postautologous Peripheral Blood Hematopoietic Stem Cell Transplantation

S. Ansell, S. Markovic, W. Hogan, 2013, Bone marrow research.

Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.

Ruta Bajorunaite, Arturo Molina, John Gibson, 2003, Blood.

Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation.

D. Dingli, S. Ansell, A. Dispenzieri, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Infused autograft lymphocyte to monocyte ratio predicts survival in classical Hodgkin lymphoma

S. Ansell, S. Markovic, W. Hogan, 2015, Journal of blood medicine.

Infused Autograft Lymphocyte to Monocyte Ratio and Survival in Classical Hodgkin Lymphoma

S. Ansell, S. Markovic, W. Hogan, 2014 .

Infused autograft lymphocyte to monocyte ratio and survival in diffuse large B cell lymphoma.

S. Ansell, S. Markovic, W. Hogan, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure.

Alan M. Miller, J. Vose, Sonali M. Smith, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

27-year-old woman with pancytopenia.

D. Rayson, D. Inwards, E. Kang, 1995, Mayo Clinic proceedings.

Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma.

J. Cerhan, P. Kurtin, T. Habermann, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Response to rituximab in patients with type II cryoglobulinemia.

A. Bryce, A. Dispenzieri, R. Kyle, 2006, Clinical lymphoma & myeloma.

Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.

S. Ansell, A. Dispenzieri, J. Katzmann, 2006, Blood.

Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study.

T. Therneau, R. Fonseca, S. Ansell, 2004, Blood.

Clinical heterogeneity of diffuse large B cell lymphoma following failure of front‐line immunochemotherapy

J. Cerhan, T. Habermann, S. Ansell, 2017, British journal of haematology.

Early event status informs subsequent outcome in newly diagnosed follicular lymphoma

J. Cerhan, G. Salles, B. Coiffier, 2016, American journal of hematology.

A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma

T. Habermann, S. Ansell, C. Reeder, 2010, American journal of hematology.

Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution.

T. Habermann, S. Ansell, S. Markovic, 2016, Blood.

Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience.

T. Habermann, H. Tun, Liuyan Jiang, 2022, Clinical lymphoma, myeloma & leukemia.

The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas

M. Kaminski, A. Feldman, T. Habermann, 2014, Blood Cancer Journal.

Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era

J. Cerhan, T. Habermann, S. Slager, 2021, American journal of hematology.

Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma

T. Habermann, S. Ansell, S. Markovic, 2010, Leukemia.

Time of relapse after initial therapy significantly adds to the prognostic value of the IPI-R in patients with relapsed DLBCL undergoing autologous stem cell transplantation

S. Ansell, S. Ansell, D. Inwards, 2008, Bone Marrow Transplantation.

Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma.

B. B. Weitner, A. Rademaker, L. Gordon, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT

J. Vose, S. Montoto, Sonali M. Smith, 2019, JAMA oncology.

Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: A phase II trial in the North Central Cancer Treatment Group

D. Moore, C. Reeder, S. Geyer, 2008, Leukemia & lymphoma.

Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma

J. Cerhan, T. Habermann, S. Ansell, 2021, Blood cancer journal.

Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study.

A. Feldman, S. Ansell, Hui Tang, 2011, The Lancet. Oncology.

Low‐dose, single‐agent temsirolimus for relapsed mantle cell lymphoma

D. Moore, S. Ansell, K. Rowland, 2008, Cancer.

Effect of lenalidomide combined with R-CHOP (R2CHOP) on negative prognostic impact of nongerminal center (non-GCB) phenotype in newly diagnosed diffuse large B-cell lymphoma: A phase 2 study.

T. Habermann, S. Ansell, C. Reeder, 2014 .

The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma

T. Habermann, S. Ansell, S. Markovic, 2012, Leukemia & lymphoma.

Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?

Jason R. Young, T. Habermann, S. Ansell, 2020, Leukemia & lymphoma.

Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis

Sonali M. Smith, R. Vij, W. Wood, 2019, Blood Cancer Journal.

Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study

T. Habermann, S. Ansell, T. Witzig, 2021, Blood cancer journal.

Hematologist/oncologist disease‐specific expertise and survival: Lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)

Deborah A. Bowen, T. Shanafelt, S. Slager, 2012, Cancer.

Phase I Clinical Study of Atacicept in Patients with Relapsed and Refractory B-Cell Non–Hodgkin's Lymphoma

I. Nestorov, S. Ansell, S. Dillon, 2008, Clinical Cancer Research.

Primary lymphomas of bone.

D. Wenger, D. Inwards, P. Gill, 2005, Clinical lymphoma & myeloma.

A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed Aggressive Non-Hodgkin Lymphoma (NHL).

T. Habermann, H. Tun, C. Reeder, 2007 .

Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation.

J. Vose, S. Montoto, Sonali M. Smith, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Primary pulmonary lymphoma.

T. Habermann, D. Inwards, Paul J. Kurtin, 1999, Seminars in oncology.

AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma.

S. Markovic, D. Gastineau, D. Inwards, 2007, Clinical lymphoma & myeloma.

Dendritic Cell Vaccine Treatment for B-Cell Non-Hodgkin Lymphoma: Clinical Trial in Progress

A. Dietz, T. Atwell, S. Ansell, 2014 .

ASTCT, CIBMTR and EBMT Clinical Practice recommendations for transplant and cellular therapies in mantle cell lymphoma.

Michael L. Wang, Sonali M. Smith, J. Friedberg, 2021, Bone Marrow Transplantation.

American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma

Michael L. Wang, Sonali M. Smith, J. Friedberg, 2021, Transplantation and cellular therapy.

Infusion of autograft natural killer cell/CD14+HLA-DRDIM cell ratio predicts survival in lymphoma post autologous stem cell transplantation

S. Ansell, S. Markovic, W. Hogan, 2018, Bone Marrow Transplantation.

Lines of therapy before autologous stem cell transplant and CAR‐T affect outcomes in aggressive Non‐Hodgkin's lymphoma

T. Habermann, S. Ansell, M. Hathcock, 2021, American journal of hematology.

Outcomes of rituximab‐BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation

M. Aljurf, R. Gale, L. Lekakis, 2020, Cancer.

Phase I/II Study of Ipilimumab (MDX-010), an Anti-CTLA-4 Monoclonal Antibody, in Patients with Follicular Non-Hodgkin Lymphoma.

T. Habermann, S. Ansell, S. Geyer, 2006 .

The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen.

S. Montoto, Sonali M. Smith, J. Klein, 2015, Biology of Blood and Marrow Transplantation.

Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016

T. Habermann, P. L. Bergsagel, R. Fonseca, 2017, JAMA oncology.

Survival trends in young patients with Waldenström macroglobulinemia: Over five decades of experience

R. Kyle, Shaji K. Kumar, S. Rajkumar, 2016, American journal of hematology.

Predictors of short-term survival in Waldenström Macroglobulinemia

T. Habermann, D. Dingli, A. Dispenzieri, 2020, Leukemia & lymphoma.

Assessment of fixed‐duration therapies for treatment‐naïve Waldenström macroglobulinemia

T. Habermann, D. Dingli, A. Chanan-Khan, 2021, American journal of hematology.

Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.

T. Therneau, M. Burritt, A. Jaffe, 2004, Blood.

Rituximab-based maintenance therapy in Waldenström macroglobulinemia: A case control study.

T. Habermann, A. Dispenzieri, R. Kyle, 2019, Journal of Clinical Oncology.

Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials.

J. Cerhan, T. Molina, G. Salles, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of MYD88L265P mutation status on histological transformation of Waldenström Macroglobulinemia

T. Habermann, D. Dingli, A. Dispenzieri, 2019, American journal of hematology.

Primary systemic amyloidosis in patients with Waldenström macroglobulinemia

T. Habermann, D. Dingli, S. Ansell, 2018, Leukemia.

Outcomes with rituximab plus bendamustine (R-Benda), dexamethasone, rituximab, cyclophosphamide (DRC), and bortezomib, dexamethasone, rituximab (BDR) as primary therapy in patients with Waldenstrom macroglobulinemia (WM).

T. Habermann, A. Dispenzieri, R. Kyle, 2019, Journal of Clinical Oncology.

Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia

T. Habermann, S. Vincent Rajkumar, D. Dingli, 2018, American journal of hematology.

Paraneoplastic lower motor neuronopathy associated with Hodgkin lymphoma

Lyell K. Jones, P. Sandroni, S. Pittock, 2012, Muscle & nerve.

Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma

T. Habermann, S. Ansell, S. Markovic, 2014, Leukemia & lymphoma.

Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma

T. Habermann, S. Ansell, S. Markovic, 2012, Blood Cancer Journal.

Reply to ‘Claimed association of absolute lymphocyte count with therapeutic efficacy of radio-immunotherapy in patients with indolent lymphoma cannot be verified in an independence data set’ by Mark J Bishton et al

T. Habermann, S. Ansell, S. Markovic, 2008, Leukemia.

Absolute lymphocyte count predicts overall survival in follicular lymphomas

T. Habermann, S. Ansell, S. Markovic, 2006, British journal of haematology.

Absolute lymphocyte count predicts overall survival in follicular

T. Habermann, S. Ansell, S. Markovic, 2006 .

The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma.

T. Habermann, S. Ansell, H. Tun, 2015, Blood.

Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma

S. Ansell, D. Inwards, L. Costa, 2008, British journal of haematology.

Radioimmunotherapeutic strategies in autologous hematopoietic stem-cell transplantation for malignant lymphoma.

J. Winter, D. Inwards, J. Cilley, 2006, Best practice & research. Clinical haematology.

New-onset lymphopenia assessed during routine follow-up is a risk factor for relapse postautologous peripheral blood hematopoietic stem cell transplantation in patients with diffuse large B-cell lymphoma.

S. Ansell, S. Markovic, W. Hogan, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.

J. Vose, M. Bast, R. Fisher, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma

D. Dingli, A. Dispenzieri, S. Ansell, 2017, Bone Marrow Transplantation.

Autograft-Absolute Lymphocyte Count Infusion Predicts Survival in Double/Triple Hit Lymphomas Post-Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation

S. Ansell, S. Markovic, D. Inwards, 2021, Blood.

Immunologic Autograft Engineering: 13 Years Follow-up

S. Ansell, S. Markovic, D. Inwards, 2021, Blood.

Infused autograft-absolute lymphocyte count predicts superior survival in Diffuse Large B-Cell Lymphoma patients post-autologous peripheral blood hematopoietic stem cell transplantation: a matched-control study.

S. Ansell, S. Markovic, J. Winters, 2021, Transplantation and cellular therapy.

Day 100 Absolute Monocyte/Lymphocyte Prognostic Score and Survival Post Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation in Diffuse Large B-Cell Lymphoma

S. Ansell, S. Markovic, W. Hogan, 2013 .

Oral Tipifarnib (R115777) Has Single Agent Anti-Tumor Activity in Patients with Relapsed Aggressive Non-Hodgkin Lymphoma (NHL): Results of a Phase II Trial in the University of Iowa/Mayo Clinic Lymphoma SPORE (CA97274).

T. Habermann, S. Ansell, S. Kaufmann, 2006 .

Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR).

Alan M. Miller, J. Armitage, J. Vose, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma.

M. Perales, M. Aljurf, J. Bolaños-Meade, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Predicting Poor Peripheral Blood Stem Cell Mobilization in Multiple Myeloma (MM) Using Initial Peripheral CD34 Counts: Developing Target-Based Cut-Points for Early Intervention.

D. Dingli, A. Dispenzieri, Shaji K. Kumar, 2009 .

Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant.

M. Aljurf, L. Lekakis, N. Ghosh, 2020, JAMA oncology.

Prior Rituximab Exposure Does Not Appear to Affect Time to Treatment Failure After Radioimmunotherapy

T. Habermann, S. Ansell, T. Witzig, 2011 .

Absolute monocyte/lymphocyte count prognostic score is independent of immunohistochemically determined cell of origin in predicting survival in diffuse large B-cell lymphoma

T. Habermann, S. Ansell, S. Markovic, 2012, Leukemia & lymphoma.

Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte‐predominant Hodgkin lymphoma

T. Habermann, S. Ansell, S. Markovic, 2012, British journal of haematology.

Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin’s lymphoma

T. Habermann, S. Ansell, S. Markovic, 2012, Haematologica.

Positive positron emission tomography (PET) pre-autologous stem cell transplant (ASCT) in non-Hodgkin lymphoma (NHL) does not preclude successful outcome

V. Lowe, S. Ansell, D. Inwards, 2006 .

Transplantation for Immunoglobulin Light Chain Amyloidosis. A Statistical Analysis of Factors Predicitng Outcome In Over 400 Patients

D. Dingli, A. Dispenzieri, Shaji K. Kumar, 2010 .

A Phase 2 Study Of Lenalidomide, Rituximab, Cyclophosphamide and Dexamethasone (LR-CD) For Untreated Low Grade Non-Hodgkin Lymphoma Requiring Therapy: Waldenström’s Macroglobulinemia Cohort Results

Macp, Chb, T. Habermann, 2013 .

The mTORC 1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma

T. Habermann, S. Ansell, H. Tun, 2015 .

Impact of Cell of Origin on Outcomes After Autologous Hematopoietic Cell Transplant in Diffuse Large B-Cell Lymphoma.

S. Ansell, H. Tun, C. Reeder, 2021, Clinical lymphoma, myeloma & leukemia.

Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation

J. Vose, P. Riedell, Sonali M. Smith, 2021, British journal of haematology.

Combination of lenalidomide with R-CHOP (R2CHOP) as an initial therapy for aggressive B-cell lymphomas: A phase I/II study.

T. Habermann, S. Ansell, C. Reeder, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chronic lymphocytic leukemia (CLL) with Reed–Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?

P. Kurtin, T. Habermann, S. Slager, 2022, Blood cancer journal.

Germinal center B (GCB) and non‐GCB cell‐like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation

A. Feldman, S. Ansell, D. Inwards, 2008, British journal of haematology.

History of autoimmune conditions and lymphoma prognosis

J. Cerhan, C. Flowers, A. Feldman, 2018, Blood Cancer Journal.

Survival in patients with limited-stage peripheral T-cell lymphomas

M. Kaminski, A. Feldman, T. Habermann, 2015, Leukemia & lymphoma.

Combination of Lenalidomide with R-CHOP (R2CHOP) Is Well-Tolerated and Effective As Initial Therapy for Aggressive B-Cell Lymphomas - A Phase II Study

T. Habermann, S. Ansell, C. Reeder, 2012 .

A Risk Adapted Approach Utilizing Plerixafor In Autologous Peripheral Blood Stem Cell Mobilization

D. Dingli, A. Dispenzieri, S. Ansell, 2010 .

Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma.

J. Cerhan, T. Habermann, S. Ansell, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Timing of autologous stem cell transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphoma

S. Ansell, S. Markovic, D. Gastineau, 2006, British journal of haematology.

Effect of AMD3100 on T Lymphocyte Subpopulations in Apheresis Products of Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation for Non Hodgkin Lymphoma.

A. Dispenzieri, Shaji K. Kumar, M. Gertz, 2005 .

Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant

J. Cerhan, T. Habermann, S. Ansell, 2023, HemaSphere.

Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.

R. Gascoyne, T. Habermann, S. Ansell, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Acquired C1 esterase inhibitor deficiency (multiple letters)

M. López-Trascasa, S. Markovic, M. Cicardi, 2000 .

90Y Ibritumomab Tiuxetan (Zevalin®; 90YZ) Doses Calculated To Deliver up to 1500 cGy to Critical Organs May Be Safely Combined with High-Dose BEAM and Autotransplant in NHL.

A. Rademaker, L. Gordon, J. Winter, 2006 .

Initial results of a pilot study of epratuzumab and rituximab in combination with CHOP chemotherapy (ER-CHOP) in previously untreated patients with diffuse large B-cell lymphoma (DLBCL).

T. Habermann, S. Horning, S. Ansell, 2004, Journal of Clinical Oncology.

T. Habermann, S. Ansell, T. Witzig, 2021, Blood Cancer Journal.

A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant for hematologic malignancies using cladribine, thiotepa and rabbit antithymocyte globulin

S. Ansell, A. Dispenzieri, A. Tefferi, 2013, Leukemia & lymphoma.

Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B‐ and T‐cell non‐Hodgkin lymphoma

J. Cerhan, T. Habermann, S. Ansell, 2014, American journal of hematology.

PD-1 Blockade with Pembrolizumab in Relapsed Low Grade Non-Hodgkin Lymphoma

A. Feldman, T. Habermann, D. Northfelt, 2017 .

Anti-Tumor Activity of Single-Agent CCI-779 for Relapsed Mantle Cell Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group.

R. Fonseca, K. Rowland, S. Dakhil, 2004 .

Diagnosis-to-Treatment Interval (DTI) Remains Associated with Adverse Clinical Characteristics and Outcome in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma Treated on Clinical Trials

J. Cerhan, T. Molina, G. Salles, 2017 .

Widespread use of complementary and alternative medicine among non-Hodgkin lymphoma survivors

J. Cerhan, T. Habermann, S. Ehlers, 2015, Leukemia & lymphoma.

Everolimus Plus RCHOP-21 Is Safe and Highly Effective for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Phase I Trial NCCTG1085 (Alliance)

T. Habermann, S. Ansell, T. Witzig, 2015 .

90: Autologous Stem Cell Transplant (ASCT) in First Remission for Patients with Mantle Cell Lymphoma is Associated with Prolonged Survival

S. Ansell, D. Inwards, M. Siddiqui, 2008 .

Infused autograft lymphocyte-to-monocyte ratio and survival in T-cell lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation

S. Ansell, S. Markovic, W. Hogan, 2015, Journal of Hematology & Oncology.

Treatment Patterns and Outcomes of DLBCL after Failure of Front-Line Immunochemotherapy

J. Cerhan, T. Habermann, S. Ansell, 2015 .

Acute neuropathies after peripheral blood stem cell and bone marrow transplantation

E. Wijdicks, A. Dispenzieri, A. Rabinstein, 2003, Muscle & nerve.

Phase 1 Trial of Sorafenib and Everolimus In Patients with Lymphoma or Multiple Myeloma.

S. Ansell, Shaji K. Kumar, M. Gertz, 2010 .

Absolute Lymphocyte/Monocyte Ratio at Diagnosis and Interim Positron-Emission Tomography Predict Survival in Classical Hodgkin Lymphoma

T. Habermann, S. Ansell, S. Markovic, 2013 .

Use of radioimmunotherapy in stem cell transplantation and posttransplantation: focus on yttrium 90 ibritumomab tiuxetan.

A. Nademanee, J. Winter, I. Flinn, 2007, Current stem cell research & therapy.

A Phase I Trial of CpG-7909, Rituximab Immunotherapy, and Y90 Zevalin Radioimmunotherapy for Patients (Pts) with Previously Treated CD20+ Non-Hodgkin Lymphoma (NHL).

T. Habermann, T. Shanafelt, S. Ansell, 2007 .

A Phase II Study of Temsirolimus (CCI-779) in Combination with Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma.

S. Ansell, T. Witzig, Patricia A. Koenig, 2009 .

Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease

Shaji K. Kumar, A. Tefferi, M. Gertz, 2002, Bone Marrow Transplantation.

ECOG-ACRIN E1411 randomized phase 2 trial of bendamustine-rituximab (BR)-based induction followed by rituximab (R) ± lenalidomide (L) consolidation for Mantle cell lymphoma: Effect of adding bortezomib to front-line BR induction on PFS.

J. Friedberg, J. Leonard, N. Bartlett, 2021 .

Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma

J. Cerhan, J. Leonard, A. Feldman, 2022, Blood advances.

Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines

T. Habermann, R. Fonseca, D. Dingli, 2010 .

Waldenström Macroglobulinemia in the Very Elderly (≥75 years):Clinical Characteristics and Outcomes

T. Habermann, D. Dingli, A. Dispenzieri, 2020 .

Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting

T. Habermann, D. Dingli, A. Dispenzieri, 2018, Blood.

Prognosis of Patients with Waldenström Macroglobulinemia: A Simplified Model

T. Habermann, D. Dingli, A. Dispenzieri, 2018, Blood.

Combined positron emission tomography/computed tomography for evaluation of presumed choroidal metastases

J. Pulido, B. Mullan, D. Inwards, 2006, Clinical & experimental ophthalmology.

Alemtuzumab Use and Survival After Reduced Intensity Allogeneic Stem Cell Transplantation in High-Risk Chronic Lymphocytic Leukemia (CLL),

T. Shanafelt, S. Slager, N. Kay, 2011 .

Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma

S. Ansell, S. Markovic, D. Gastineau, 2006, Bone Marrow Transplantation.

Secondary cutaneous involvement by systemic anaplastic lymphoma kinase‐negative anaplastic large‐cell lymphoma with 6p25.3 rearrangement

A. Feldman, D. Inwards, K. L. Grogg, 2015, Histopathology.

Phase II study of rituximab and cladribine (2-CDA) in newly diagnosed mantle cell lymphoma (MCL) (N0189).

S. Dakhil, R. Morton, W. White, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Study of Ipilimumab, an Anti–CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non–Hodgkin Lymphoma

T. Habermann, S. Ansell, I. Lowy, 2009, Clinical Cancer Research.

Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?

J. Vose, Sonali M. Smith, P. Hari, 2012, Blood.

Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study

J. Cerhan, T. Habermann, S. Ansell, 2023, Blood cancer journal.

A Phase I/II Trial of Lenalidomide and RCHOP (R2CHOP) in Patients with Newly Diagnosed Diffuse Large B -Cell (DLBCL) and Follicular Grade 3 Lymphoma.

T. Habermann, C. Reeder, T. Witzig, 2009 .

The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen.

S. Montoto, Sonali M. Smith, D. Maloney, 2015, Biology of Blood and Marrow Transplantation.

Primary systemic amyloidosis in patients with Waldenström macroglobulinemia

T. Habermann, D. Dingli, S. Ansell, 2018, Leukemia.

Outcomes in primary cutaneous diffuse large B‐cell lymphoma, leg type

T. Habermann, S. Ansell, T. Witzig, 2021, Hematological oncology.

S. Ansell, D. Inwards, L. Costa, 2008, British journal of haematology.

Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma

J. Vose, M. Bast, F. Hernandez-Ilizaliturri, 2023, Blood advances.

Patterns of progression after immune checkpoint inhibitors for Hodgkin lymphoma: implications for radiation therapy

T. Habermann, T. Witzig, D. Inwards, 2024, Blood advances.

Outcomes of limited stage primary bone diffuse large B-cell lymphoma in the rituximab era: a multicenter, retrospective study.

N. Bartlett, M. Lunning, S. Chowdhury, 2023, Haematologica.

Infusion of autograft natural killer cell/CD14+HLA-DRDIM cell ratio predicts survival in lymphoma post autologous stem cell transplantation

S. Ansell, S. Markovic, D. Inwards, 2018, Bone Marrow Transplantation.

Survival trends in young patients with Waldenström macroglobulinemia: Over five decades of experience

S. Ansell, Shaji K. Kumar, S. Rajkumar, 2023, American journal of hematology.

Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution.

T. Habermann, S. Ansell, S. Markovic, 2016, Blood.

Central nervous system involvement by mantle cell lymphoma

T. Habermann, S. Ansell, T. Witzig, 2022, Leukemia & lymphoma.

Lower GVHD and relapse risk in PTCy-based Haploidentical vs Matched Sibling Donor RIC Transplant for Hodgkin Lymphoma

M. Aljurf, J. Bolaños-Meade, Y. Nieto, 2019 .

COVID-19 outcome is not affected by anti-CD20 or high-titer convalescent plasma in immunosuppressed patients

M. J. Kasten, R. Razonable, D. Inwards, 2023, Scientific reports.

Correction: Propranolol and Thyroid Storm.

S. Markovic, Markovic, D. Inwards, 2000, Annals of Internal Medicine.